Terns Pharmaceuticals TERN Stock
Terns Pharmaceuticals Price Chart
Terns Pharmaceuticals TERN Financial and Trading Overview
| Terns Pharmaceuticals stock price | 52.95 USD |
| Previous Close | 52.97 USD |
| Open | 52.97 USD |
| Bid | 38.13 USD x 200 |
| Ask | 67.8 USD x 200 |
| Day's Range | 52.97 - 52.97 USD |
| 52 Week Range | 2.66 - 53.19 USD |
| Volume | 6.33M USD |
| Avg. Volume | 5.92M USD |
| Market Cap | 6.12B USD |
| Beta (5Y Monthly) | -0.38 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -1.03 USD |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 53 USD |
TERN Valuation Measures
| Enterprise Value | 5.09B USD |
| Trailing P/E | N/A |
| Forward P/E | -34.01492 |
| PEG Ratio (5 yr expected) | N/A |
| Price/Sales (ttm) | N/A |
| Price/Book (mrq) | 5.9089384 |
| Enterprise Value/Revenue | N/A |
| Enterprise Value/EBITDA | -46.286 |
Trading Information
Terns Pharmaceuticals Stock Price History
| Beta (5Y Monthly) | -0.38 |
| 52-Week Change | 1797.84% |
| S&P500 52-Week Change | 24.48% |
| 52 Week High | 53.19 USD |
| 52 Week Low | 2.66 USD |
| 50-Day Moving Average | 50.15 USD |
| 200-Day Moving Average | 29.48 USD |
TERN Share Statistics
| Avg. Volume (3 month) | 5.92M USD |
| Avg. Daily Volume (10-Days) | 2.44M USD |
| Shares Outstanding | 115.52M |
| Float | 115.12M |
| Short Ratio | 0.7 |
| % Held by Insiders | 0.25% |
| % Held by Institutions | 109.68% |
| Shares Short | 8.06M |
| Short % of Float | 6.99% |
| Short % of Shares Outstanding | 6.98% |
Dividends & Splits
| Trailing Annual Dividend Rate | 0 |
| Trailing Annual Dividend Yield | 0% |
| 5 Year Average Dividend Yield | N/A |
| Payout Ratio | 0 |
| Last Split Factor |
Financial Highlights
Fiscal Year
| Fiscal Year Ends | December 31, 2025 |
| Most Recent Quarter (mrq) | December 31, 2025 |
| Next Fiscal Year End | December 31, 2026 |
Profitability
| Profit Margin | 0% |
| Operating Margin (ttm) | 0% |
| Gross Margin | 0% |
| EBITDA Margin | 0% |
Management Effectiveness
| Return on Assets (ttm) | -9.91% |
| Return on Equity (ttm) | -14.22% |
Income Statement
| Revenue (ttm) | N/A |
| Revenue Per Share (ttm) | N/A |
| Quarterly Revenue Growth (yoy) | N/A |
| Gross Profit (ttm) | N/A |
| EBITDA | -110034000 USD |
| Net Income Avi to Common (ttm) | -96207000 USD |
| Diluted EPS (ttm) | -1.03 |
| Quarterly Earnings Growth (yoy) | N/A |
Balance Sheet
| Total Cash (mrq) | 1.02B USD |
| Total Cash Per Share (mrq) | 8.83 USD |
| Total Debt (mrq) | 919K USD |
| Total Debt/Equity (mrq) | 0.09 USD |
| Current Ratio (mrq) | 62.409 |
| Book Value Per Share (mrq) | 8.961 |
Cash Flow Statement
| Operating Cash Flow (ttm) | -82176000 USD |
| Levered Free Cash Flow (ttm) | -55480500 USD |
Profile of Terns Pharmaceuticals
| Country | United States |
| State | CA |
| City | Foster City |
| Address | 1065 East Hillsdale Boulevard |
| ZIP | 94404 |
| Phone | 650 525 5535 |
| Website | https://www.ternspharma.com |
| Industry | Biotechnology |
| Sector(s) | Healthcare |
| Full Time Employees | 59 |
Terns Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops small-molecule product candidates for the treatment of oncology and obesity. The company develops TERN-701, an allosteric BCR-ABL tyrosine kinase inhibitor (TKI) that is in Phase 1/2 clinical trial for chronic myeloid leukemia (CML), a form of cancer that starts in bone marrow. It also develops TERN-501, a thyroid hormone receptor beta agonist with enhanced metabolic stability and liver distribution that is in Phase IIa clinical trial for the treatment of metabolic dysfunction-associated steatohepatitis (MASH); and TERN-801 series of small-molecule glucose-dependent insulinotropic polypeptide receptor (GIPR) modulators for obesity. The company was incorporated in 2016 and is headquartered in Foster City, California. As of May 4, 2026, Terns Pharmaceuticals, Inc. operates as a subsidiary of Merck Sharp & Dohme LLC.
Q&A For Terns Pharmaceuticals Stock
What is a current TERN stock price?
Terns Pharmaceuticals TERN stock price today per share is 52.95 USD.
How to purchase Terns Pharmaceuticals stock?
You can buy TERN shares on the Tech Market Large exchange. Contact your financial advisor to select a broker.
What is the ticker symbol for Terns Pharmaceuticals?
The stock symbol or ticker of Terns Pharmaceuticals is TERN.
Which industry does the Terns Pharmaceuticals company belong to?
The Terns Pharmaceuticals industry is Biotechnology.
How many shares does Terns Pharmaceuticals have in circulation?
The max supply of Terns Pharmaceuticals shares is 115.52M.
What is Terns Pharmaceuticals Price to Earnings Ratio (PE Ratio)?
Terns Pharmaceuticals PE Ratio is now.
What was Terns Pharmaceuticals earnings per share over the trailing 12 months (TTM)?
Terns Pharmaceuticals EPS is -1.03 USD over the trailing 12 months.
Which sector does the Terns Pharmaceuticals company belong to?
The Terns Pharmaceuticals sector is Healthcare.
Terns Pharmaceuticals TERN included in indexes
| Name Name | Price Price |
24h% 7d chart 24h% & 7d |
VOL Volume | 24h low | 24h high | Volume |
|---|
| Name Name | Price Price |
24h% 7d chart 24h% & 7d |
VOL Volume | 24h low | 24h high | Volume | |
|---|---|---|---|---|---|---|---|
|
|
{{ item.price }} {{ item.price_usd }} |
{{ item.change_pct }}
|
{{ item.volume }} {{ item.volume_usd }} | {{ item.low }} {{ item.low_usd }} | {{ item.high }} {{ item.high_usd }} | {{ item.components_count }} - | {{ item.volume }} {{ item.volume_usd }} |
US Tech Composite
IXIC
US
|
25587.04 USD — |
-2.21
|
13.74B USD — | 25513.26 USD — | 25882.57 USD — | — - | 13.74B USD — |
|
US Tech Global Select Market Com
NQGS
US
|
12546.99 USD — |
-2.24
|
— — | 12513.27 USD — | 12692.24 USD — | — - | — — |
|
US Tech Biotechnology
NBI
US
|
6185.56 USD — |
+0.85
|
— — | 6121.03 USD — | 6233.73 USD — | — - | — — |
|
US Tech Health Care
IXHC
US
|
1184.66 USD — |
+0.75
|
— — | 1174.72 USD — | 1192.68 USD — | — - | — — |
|
Stlmt ID US Tech Biotechnology
NBX
US
|
3995.9 USD — |
-4.37
|
— — | 4555.41 USD — | 4917.8 USD — | — - | — — |
- {{ link.label }} {{link}}